A risk-management approach for effective integration of biomarkers in clinical trials: perspectives of an NCI, NCRI, and EORTC working group

详细信息    查看全文

• 作者：Dr Jacqueline Anne Hall ; PhD^a ; ^{jacqueline.a.hall@gmail.com" class="auth_mail} ; Roberto Salgado ; MD^b ; ^c ; Tracy Lively ; PhD^d ; Prof Fred Sweep ; PhD^e ; Anna Schuh ; MD^f
• 刊名：Lancet Oncology
• 出版年：April, 2014
• 年：2014
• 卷：15
• 期：4
• 页码：e184-e193
• 全文大小：121 K

文摘

| Figures/TablesFigures/Tables | ReferencesReferences

Summary

Clinical cancer research today often includes testing the value of biomarkers to direct treatment and for drug development. However, the practical challenges of integration of molecular information into clinical trial protocols are increasingly appreciated. Inherent difficulties include evidence gaps in available biomarker data, a paucity of robust assay methods, and the design of appropriate studies within the constraints of feasible trial operations, and finite resources. Scalable and proportionate approaches are needed to systematically cope with these challenges. Therefore, we assembled international experts from three clinical trials organisations to identify the common challenges and common solutions. We present a practical risk-assessment framework allowing targeting of scarce resources to crucial issues coupled with a library of useful resources and a simple actionable checklist of recommendations. We hope that these practical methods will be useful for running biomarker-driven trials and ultimately help to develop biomarkers that are ready for integration in routine practice.